# Neoadjuvant SNF Precision Therapy Phase III

> **NCT06913777** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 404 (estimated)

## Conditions studied

- Neoadjuvant Therapy

## Interventions

- **DRUG:** Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib
- **DRUG:** Chemotherapy (wP-EC)

## Key facts

- **NCT ID:** NCT06913777
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-08
- **Primary completion:** 2026-10-15
- **Final completion:** 2027-04-15
- **Target enrollment:** 404 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06913777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06913777, "Neoadjuvant SNF Precision Therapy Phase III". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06913777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*